Opinion

Video

High Risk Populations in the Development of Prostate Cancer

Author(s):

Benjamin H. Lowentritt, MD, FACS,Brian Richardson, MD

The key opinion leaders explore risk factors for prostate cancer, detailing both general risk groups and high-risk populations more susceptible to developing the disease.

Current Time 0:00
Duration 3:41
Loaded: 4.44%
Stream Type LIVE
Remaining Time 3:41
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following question:

    • We know that some patient populations are at a higher risk for developing prostate cancer. Please briefly discuss the general risk groups in prostate cancer.
    Related Videos
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    1 expert in this video
    Comparing Trials Studying Treatment Intensification In mHSPC
    An Overview of the ARANOTE Trial
    An Overview of the ARANOTE Trial
    Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
    Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
    Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
    Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
    Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
    Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
    Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
    Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Related Content
    Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
    May 13th 2025

    MRI and focal therapy may enable men on AS to safely delay surgery or radiation

    Hannah Clarke
    Use of focal therapy was shown to prolong the duration of active surveillance.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
    May 2nd 2025

    Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

    Hannah Clarke
    The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    ARANOTE substudy highlights benefits of darolutamide in Black men
    April 28th 2025

    ARANOTE substudy highlights benefits of darolutamide in Black men

    Benjamin P. Saylor
    The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
    Stephen J. Freedland, MD
    April 28th 2025

    Most men in EMBARK trial recover T levels following treatment suspension

    Benjamin P. Saylor
    More than 80% of patients in both groups had a full recovery of testosterone.
    © 2025 MJH Life Sciences

    All rights reserved.